Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
D-dimer to Predict Recurrence in Patients With Multiple Episodes of Venous Thromboembolism
- Conditions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Università degli Studi dell'Insubria
- Target Recruit Count
- 73
- Registration Number
- NCT00428441
- Locations
- 🇮🇹
University Of Insubria, Varese, Italy
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20976
- Registration Number
- NCT00412984
- Locations
- 🇺🇸
David Charles Mishkel, Md, Pa, Boca Raton, Florida, United States
🇺🇸Heart Care Center, P.C., East Syracuse, New York, United States
🇺🇸Elkhart Clinic, Llc, Elkhart, Indiana, United States
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
- First Posted Date
- 2006-11-27
- Last Posted Date
- 2014-04-29
- Target Recruit Count
- 14269
- Registration Number
- NCT00403767
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
- Conditions
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2013-08-30
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 344
- Registration Number
- NCT00401414
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2016-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3202
- Registration Number
- NCT00345618
- Locations
- 🇷🇺
Sanofi-Aventis Admnistrative Office, Moscow, Russian Federation
🇬🇧Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
Secondary Prevention of Venous Thrombo Embolism (VTE).
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2867
- Registration Number
- NCT00329238
- Locations
- 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico
Pilot Study of Aspirin Versus Warfarin for Cervicocephalic Arterial Dissection
- First Posted Date
- 2005-12-14
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- University of California, San Diego
- Registration Number
- NCT00265408
- Locations
- 🇺🇸
UCSD Medical Center, San Diego, California, United States
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
- Conditions
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18113
- Registration Number
- NCT00262600
- Locations
- 🇸🇪
1160.26.1633 Sahlgrenska Sjukhuset, Göteboerg, Sweden
🇺🇸1160.26.0278 Boehringer Ingelheim Investigational Site, Bridgeport, Connecticut, United States
🇺🇸1160.26.0358 Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
- Conditions
- First Posted Date
- 2005-11-02
- Last Posted Date
- 2005-11-02
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT00247702
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Treatment of Upper Extremity Deep-Vein Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 67
- Registration Number
- NCT00245856
- Locations
- 🇺🇸
Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.